COMMUNIQUÉS West-GlobeNewswire

-
GT Biopharma Provides Enrollment Update on GTB-3650 Phase 1 Trial in Patients with Relapsed or Refractory (r/r) CD33 Expressing Hematologic Malignancies
08/10/2025 -
Mainz Biomed Reports Topline Results from Feasibility Study of Biomarker Panel in Pancreatic Cancer Project
08/10/2025 -
Predictive Oncology Inc. Announces Closing of $343.5 Million in Private Placements to Initiate Digital Asset Treasury Strategy
08/10/2025 -
InterCure Reports First Half 2025 Results with NIS 130 Million in Revenue and Positive Operating Cash Flow
08/10/2025 -
Long Life Family Study Taps PacBio HiFi Sequencing to Unlock Genetic and Epigenetic Clues to Exceptional Longevity
08/10/2025 -
Intuitive expands AI and advanced imaging integration in Ion Endoluminal System
08/10/2025 -
InterCure Reports First Half 2025 Results with NIS 130 Million in Revenue and Positive Operating Cash Flow
08/10/2025 -
Triumph Steps Scales Proven Transformative Coaching Certification for Mental Health Professionals
08/10/2025 -
Baylor Genetics to Showcase Clinical and Diagnostic Utility of Genome Sequencing and Multi-omics Across Rare Disease at the American Society of Human Genetics 2025 Annual Meeting
08/10/2025 -
Sai Life Sciences, Agility Life Sciences, and Centrix Pharma Solutions announce an ‘Integrated CMC Partnership’ to accelerate drug development for innovators
08/10/2025 -
Zenas BioPharma and InnoCare Pharma Announce License Agreement Granting Zenas Rights for Three Autoimmune Product Candidates, Including Orelabrutinib, a BTK Inhibitor in Phase 3 Development for Multiple Sclerosis
08/10/2025 -
Confo Therapeutics Awarded VLAIO Grant for Development of Ultra-Long-Acting Antibody-Based GPCR Therapeutics in Endocrine and Metabolic Conditions
08/10/2025 -
Immuron Submits IMM-529 IND to FDA
08/10/2025 -
FDA Clears Celon Pharma’s Schizophrenia Drug for Phase 3 Trial
08/10/2025 -
ITM Presents Dosimetry Data from Phase 3 COMPETE Trial Supporting Favorable Efficacy and Safety Profile with n.c.a. 177Lu-edotreotide (ITM-11) in Patients with Gastroenteropancreatic Neuroendocrine Tumors at EANM 2025 Annual Congress
08/10/2025 -
Newcastle Set To Benefit From New Technology to Diagnose Disease
08/10/2025 -
Oxford Set To Benefit From New Technology to Diagnose Disease
08/10/2025 -
Dr. Anita Gupta of the University of California, Riverside, named the 2025 Recipient of the Arnold P. Gold Humanism in Medicine Award
08/10/2025 -
CervoMed Announces New Data from Phase 2b Trial Demonstrating Neflamapimod's Potential as a Treatment for Dementia with Lewy Bodies
08/10/2025
Pages